These systemic effects, which we have already touched upon, also include the complex interplay between CFTR modulator therapy and other common CF manifestations, such as digestive dysfunction and CF-related diabetes (CFRD). The gene discussed is CFTR; the disease is cystic fibrosis-related diabetes.